SynthesisFrontiers in medicine2026
The efficacy of traditional Chinese medicine on immune function in patients with hepatitis B-related liver fibrosis or cirrhosis: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Currently, there is no effective treatment to reverse hepatitis B-related liver fibrosis or cirrhosis. Current nucleos(t)ide analogs (NAs) control but rarely eliminate hepatitis B virus (HBV), leaving chronic hepatitis B at risk of developing liver fibrosis/cirrhosis. Traditional Chinese medicine (TCM) shows promise in slowing the progression of hepatitis B-related liver fibrosis/cirrhosis, but its impact on immune function remains debated. Methods: The electronic databases, including Chinese National Knowledge Infrastructure, Wanfang, SinoMed, Weipu, PubMed, Web of Science, EMBASE, and Cochrane databases, were retrieved (April 7, 2026), and the randomized controlled trials (RCTs) that met the inclusion criteria were included. Methodologic quality assessment of the included RCTs was done based on the Cochrane RoB 2 tool. Subsequently, the valid data were screened and analyzed by meta-analysis with Review Manager 5.4.1, and the quality of the evidence was assessed using the GRADE method. This study was registered in the PROSPERO (CRD420261351373). Results: Finally, 25 RCTs were included, containing 2,585 patients with hepatitis B-related liver fibrosis or cirrhosis. Risk of bias evaluations suggested some concerns for the majority of RCTs. The results of meta-analysis indicated that TCM with NAs could improve CD3 + [MD = 5.83, 95%CI (3.93, 7.73), Conclusion: A combination of NAs and TCM could improve immune cell metrics, cytokines, liver function indexes, and liver fibrosis indexes of patients with hepatitis B-related liver fibrosis or cirrhosis. Due to the low quality of research, more high-quality RCTs are needed to improve the level of evidence. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261351373.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.